Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

Vlad Ratziu, Frédéric Charlotte, A. Heurtier et al. · Gastroenterology · 2005 · 2K citations

Hepatology, Nonalcoholic Fatty Liver Disease, Liver Physiology +9

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.4K citations · Full text

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 733 citations

Metabolic Associated Steatohepatitis, Hepatology, Nonalcoholic Fatty Liver Disease +10

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 655 citations · Full text